Dapsone induced methaemoglobinaemia

Landers, Dónal; Bergin, Colleen J.; O’Leary, Aisling; Merry, C; Keating, Sarah B.; Mulcahy, Fiona

doi:10.1258/0956462961918293

Cited by 10 publications

(11 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[16][17][18][19][20][21][22][23][24][25] There have been few cases of methemoglobinemia from dapsone reported in the literature since 1985. 2,16-25 Some cases [19][20][21][22] have been the result of accidental or intentional overdoses with 20 -50 dapsone tablets.…”

Section: Literature Reviewmentioning

confidence: 99%

See 1 more Smart Citation

Dapsone-Induced Methemoglobinemia

Ward

McCarthy

1998

Ann Pharmacother

View full text Add to dashboard Cite

show abstract

Section: Literature Reviewmentioning

confidence: 99%

“…Landers et al 24 described two cases of dapsone-induced methemoglobinemia in HIV-positive patients. The first case involved a 29-year-old woman prescribed dapsone 100 mg/d for PCP prophylaxis after she developed a rash from TMP/SMX.…”

Section: Literature Reviewmentioning

confidence: 99%

Dapsone-Induced Methemoglobinemia

Ward

McCarthy

1998

Ann Pharmacother

View full text Add to dashboard Cite

show abstract

“…While more symptomatic presentations are treated with methylene blue and activated charcoal to prevent further gastrointestinal absorption. Methylene blue acts as a co-factor for the alternative pathway of the nicotinamide adenine dinucleotide phosphate (NADPH) system, to convert methaemoglobin to haemoglobin 47. However, methylene blue should not be administered in the presence of G6PD deficiency, where low levels of NADPH exist making it ineffective.…”

Section: Treatmentmentioning

confidence: 99%

Management of Pneumocystis Jirovecii pneumonia in HIV infected patients: current options, challenges and future directions

Castro¹,

Morrison-Bryant

2010

HIV

View full text Add to dashboard Cite

The discovery of the Human Immunodeficiency Virus (HIV) was led by the merge of clustered cases of Pneumocystis jirovecii Pneumonia (PCP) in otherwise healthy people in the early 80’s.1,2 In the face of sophisticated treatment now available for HIV infection, life expectancy approaches normal limits. It has dramatically changed the natural course of HIV from a nearly fatal infection to a chronic disease.3–5 However, PCP still remains a relatively common presentation of uncontrolled HIV. Despite the knowledge and advances gained in the prevention and management of PCP infection, it continues to have high morbidity and mortality rates. Trimethoprim-sulfamethoxazole (TMP-SMZ) remains as the recommended first-line treatment. Alternatives include pentamidine, dapsone plus trimethoprim, clindamycin administered with primaquine, and atovaquone. For optimal management, clinicians need to be familiar with the advantages and disadvantages of the available drugs. The parameters used to classify severity of infection are also important, as it is well known that the adjunctive use of steroids in moderate to severe cases have been shown to significantly improve outcome. Evolving management practices, such as the successful institution of early antiretroviral therapy, may further enhance overall survival rates.

show abstract

“…Os efeitos adversos relacionados aos esquemas terapêuticos empregados na hanseníase mais freqüentes são a metemoglobinemia e a anemia hemolítica associados à exposição a DDS (Coleman, 1995;Landers et al, 1996;Queiroz et al, 1997;Ward, McCarty, 1998;Salamat, Watson, 2003). Outros efeitos adversos também citados, porém com menor freqüência, são: letargia, granulocitopenia, problemas hepáticos e renais, dermatite esfoliativa, neuropatia periférica, febre, cefaléias, psicoses e fotodermatite (Pavithran, Satish, 1997;Leslie et al, 2003).…”

Section: Introductionunclassified